IDEXX Laboratories, IncNasdaq: IDXX
Health Care · Health Care Equipment
$568.71
+1.41%
Vol: 411K
Research Digest
Friday, May 1, 2026
UBS downgrades IDEXX to Neutral with $640 price target as Q1 earnings approach on May 5 with expected EPS of $3.42, up 15.5% YoY.
UBS analyst Andrea Alfonso lowered the firm's price target on IDEXX Laboratories to $640 from $730 while maintaining a Neutral rating. The company is set to report Q1 earnings on May 5, with analysts projecting EPS of $3.42 (up 15.5% year-over-year) and revenue of $1.12 billion (up 11.9%). IDEXX has announced advances in veterinary cancer care with comprehensive mast cell tumor testing for dogs, though the analyst downgrade reflects concerns about valuation at current levels.
Previous Market Intelligence
13 daysApr 30IDEXX Laboratories receives analyst upgrades with Buy rating and $712.22 target, eyes strong Q1 2026 earnings on May 5.Positive▶
IDEXX Laboratories is set to report Q1 2026 financial results on May 5 with expectations for 15.5% EPS growth year-over-year. The company recently elected Karen Peacock to its Board of Directors. IDEXX continues to demonstrate robust growth in companion animal diagnostics despite facing pressure from declining vet visits, with growing revenue per visit more than offsetting lower visit volumes. CEO Jonathan Mazelsky is transitioning to chairman with Michael Erickson succeeding as CEO. Full-year 2025 revenue reached $4.30 billion, up 10.42%. According to 9 analysts, IDXX has an average "Buy" rating with a 12-month target of $712.22, representing 23.94% upside from recent prices. Stock is down 3.72% in the past 24 hours.
Apr 29IDEXX Laboratories raises FY2026 guidance after Q1 beat; CEO succession planned with Mazelsky to chairmanPositive▶
IDEXX Laboratories reported better-than-expected Q4 2025 results and raised FY2026 guidance, betting on resilient demand at veterinary clinics and higher testing per visit. CEO Jonathan Mazelsky transitioning to chairman with Michael Erickson set to succeed as CEO. Stock price $574.95 with market cap of $46.09B. Zacks upgraded IDEXX to Buy rating with fresh analyst optimism on U.K. rollout of Cancer Dx Panel. Upcoming Q1 earnings on May 5 expected to show 15.5% EPS growth YoY. Nine analysts average rating Buy with $712.22 price target (+23.94% upside).
Apr 16IDEXX Laboratories stock rallied 41.8% over past year with CEO Jonathan Mazelsky transitioning to chairman; earnings report set for May 5.Positive▶
IDEXX Laboratories reported strong Q4 2025 revenue growth of 10.42% ($4.30B) with earnings up 19.33%. CEO Jonathan Mazelsky is transitioning to chairman with Michael Erickson taking the CEO role. The company advances veterinary cancer care with new mast cell tumor testing. Earnings will be reported May 5. Piper Sandler raised its price target to $775 from $700, while Stifel lowered theirs to $675. The consensus rating is "Buy" with a 12-month target of $712.22, up 23.94%.
Apr 15IDEXX launches Cancer Dx Panel in UK for canine lymphoma detection; announces planned CEO transition for May 2026.Mixed▶
IDEXX Laboratories launched its Cancer Dx Panel in the UK on April 1, 2026, offering blood-based early detection testing for lymphoma in at-risk dogs. CEO Jonathan Mazelsky will transition to chairman with Michael Erickson becoming CEO on May 12. Q1 2026 results are scheduled for May 5 release.
Apr 14IDEXX EVP Nimrata Hunt exits April 13; stock falls 3.7-4.5% on executive departure and analyst caution on 2026 outlook.Negative▶
IDEXX Laboratories announced EVP Nimrata Hunt (Global Strategy and Commercial) will exit April 13, 2026, with the role eliminated. The stock fell 3.7-4.5% due to mixed analyst sentiment on 2026 outlook and organizational changes. IDEXX launched its Cancer Dx Panel in the UK on April 1. CEO transition expected May 12, 2026. Q1 2026 earnings release scheduled for May 5 before market open.
Apr 13IDEXX launched Cancer Dx Panel in UK on April 1 for early canine lymphoma detection; confirmed 2026 guidance of 8-10% CAG organic growth.Positive▶
IDEXX launched the Cancer Dx Panel in the UK on April 1, 2026, providing blood-based early detection of lymphoma in at-risk dogs. The company projects 8-10% organic growth in companion animal diagnostics for 2026. Planned CEO transition in May 2026 will move Jonathan Mazelsky to Executive Chair and Michael Erickson to CEO. Full year 2025 revenue reached $4.3B (+10%) with EPS of $13.08 (+23%). Q1 2026 results scheduled for May 5.
Apr 10IDEXX Laboratories expands cancer detection capabilities with UK rollout of canine Cancer Dx Panel; Q1 earnings due May 5.Positive▶
IDEXX Laboratories rolled out its Cancer Dx Panel in the UK, marking the early detection of lymphoma in at-risk dogs with results in 3-5 business days. Q1 2026 results are scheduled for May 5 before market open. Nine of 15 analysts carry buy/outperform ratings with a mean price target of $742.54, implying 28.6% upside.
Apr 9IDEXX Laboratories announces Q1 2026 earnings for May 5; CEO succession and UK cancer test rollout underscore innovationPositive▶
IDEXX Laboratories scheduled Q1 2026 financial results release for Tuesday, May 5, 2026 before market open with analyst conference call at 8:30 a.m. ET. Company announced planned CEO succession with Jonathan Mazelsky transitioning to chairman and Michael Erickson becoming CEO, signaling smooth leadership transition. Major product expansion underway with UK rollout of early canine cancer test, potentially reshaping preventive care narrative for veterinary diagnostics. Stock up 1.39% in recent session to $575.27. Stifel lowered price target to $675 from $775 on March 31, though 9 analysts maintain Buy consensus with average target of $712.22, representing 23.94% upside. Headquartered in Maine with 11,000 employees and presence in 175+ countries.
Apr 8IDEXX Laboratories reports Q4 2025 revenue $1.091B; Stifel lowers price target to $675Positive▶
IDEXX Laboratories reported strong Q4 2025 with revenues of $1.091B (14% reported/12% organic growth) and diluted EPS of $3.08, up 18% as reported. Full-year 2025 revenue reached $4.30B with earnings up 19.33% vs. prior year. The company forecast 2026 revenue and profit above Wall Street estimates betting on resilient veterinary clinic demand and higher testing per visit. Stifel lowered its price target to $675 from $775 on March 31. IDEXX advanced veterinary cancer care with mast cell tumor testing and launched cancer detection panel in UK.
Apr 7IDEXX CEO succession; Erickson succeeds Mazelsky; Q4 beat and 2026 guide raise.Positive▶
IDEXX CEO succession: Michael Erickson succeeded Jonathan Mazelsky in Jan 2026. Q4 results beat estimates with 2026 guidance above expectations. Stock $577.44 (+1.39%). Revenue +10.42% to $4.30B in 2025. 9 analysts target $715 (+27.15%).
Apr 6IDEXX launches Cancer Dx Panel in UK, beats earnings with leadership transition aheadPositive▶
IDEXX Laboratories beat Q4 2025 estimates with EPS of $3.08 vs $2.93 expected and raised 2026 guidance above Street estimates. The company launched its Cancer Dx Panel for early lymphoma detection in UK practices on April 2, 2026. Shares are down 14.44% in the past month to $577, but analyst consensus is "Buy" with average target of $715, representing 27% upside.
Apr 3IDEXX Laboratories launches Cancer Dx Panel in UK and announces executive departure with strategic reorganization.Negative▶
IDEXX launched its Cancer Dx Panel in the United Kingdom on April 1 for early lymphoma detection in dogs. Executive VP Nimrata Hunt departs effective April 13, 2026, with her position being eliminated. Separation agreement totals over $2.2 million. Stifel Nicolaus cut its price target from $775 to $675. Stock fell 25% below its 52-week high of $769.98.
Apr 2IDEXX Laboratories stock up 0.46% on strong Q4 results and positive 2026 guidance; 9 analysts maintain average Buy rating with $715 PT.Positive▶
IDEXX Laboratories shares rose $3.25 (0.46%) overnight to close at $715.37 on April 2, 2026. The company reported better-than-expected Q4 results and issued fiscal 2026 guidance above Wall Street estimates, with 2025 revenue of $4.30 billion (up 10.42% YoY). Recent product innovations include expansion of the Cancer Dx Panel and inVute Dx FNA cytology rollout for veterinary cancer care. CEO Michael Erickson took over in January 2026. The company continues benefiting from strong pet healthcare spending trends.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| IDXXIDEXX | $568.71 | +1.41% | -2.9% | 34.2x | 1.72 | $44.7B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.